A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

NCT01455701 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Idiopathic Arthritis

Interventions

DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche